Diagnosis of DCM

PreclinicalBiologic

FFirst Affiliated Hospital Xi'an Jiaotong University

Diagnosis of DCM is one of 31 biologic programs targeting Cardiomyopathy. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CardiomyopathyActive, not recruiting

CardiomyopathyPreclinical

Active, not recruiting

Competition

Competitive Landscape

37 competitors in Cardiomyopathy

#DrugCompanyPhaseTrials

Ozempic

Novo Nordisk

Approved

1 2

Bayer Aspirin

Bayer

Approved

1 3

Inspra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

2 4

Rayos

RRoxane Laboratories

Approved

2 5

Zocor

OOrganon and Co

Approved

1 6

Cordarone

WWyeth-Lederle Vaccines

Approved

1 7

Imuran

LLegacy Health System

Approved

1 8

Brevibloc

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Approved

1 9

Inpefa

LLexicon Pharmaceuticals

Approved

—10

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2030

Not yet recruiting

Risk Stratification

NCT06504056

Q3 2032

Recruiting

Cardiomyopathy

NCT06352320

Clinical

Trials by Indication[1]

Cardiomyopathy1 trial

Risk Stratification and New Early Prevention and Treatment Strategies for Patients With Cardiomyopathy (STRENGTH）

Recruiting·FFirst Affiliated Hospital Xi'an Jiaotong University··NCT06352320·500 enrolled

Risk Stratification1 trial

Risk Stratification and Early Prevention Strategies for Non-compaction of Ventricular Myocardium (CAPTAIN)

Not yet recruiting·FFirst Affiliated Hospital Xi'an Jiaotong University··NCT06504056·2,000 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Diagnosis of DCM. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Diagnosis of DCM compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Diagnosis of DCM. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — First Affiliated Hospital Xi'an Jiaotong University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: FFirst Affiliated Hospital Xi'an Jiaotong University

Diagnosis of DCM

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2030

Q3 2032

Trials by Indication[1]

Cardiomyopathy1 trial

Risk Stratification1 trial

References

Drug Info

Quick Facts

Related News